Plant Name: Isoberlinia angolensis
Taxonomic Information:
Plant ID: NPO84
Plant Latin Name: Isoberlinia angolensis
Taxonomy Genus: Isoberlinia
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
859852
Plant-of-the-World-Online:
500984-1
Used in Medicines:
Unknown.
Geographical Distribution:
Angola; Sudan; Tanzania; Zambia; Burundi; Cameroon; Malawi
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; | |
| FAAH; TDP1; TERT; HPGD; ALOX15; ALDH1A1; | |
| PPARA; PPARD; PPARG; | |
| NR1I2; | |
| PTGS2; PTGS1; | |
| TLR2; | |
| ABCB1; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.571E-08 | 2.528E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 2.675E-08 | 3.641E-05 | FABP3, FFAR1, PPARG, PTGS2, TLR2 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 2.585E-07 | 2.010E-04 | NR1I2, PPARA, PPARD, PPARG |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 5.511E-07 | 3.077E-04 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 7.112E-07 | 3.872E-04 | ALOX15, HPGD, PTGS2 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 9.225E-07 | 4.783E-04 | FABP3, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.238E-06 | 5.992E-04 | PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.712E-06 | 1.470E-03 | ALOX15, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 5.383E-06 | 1.922E-03 | LMNA, PPARD, PTGS2, TERT |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 8.028E-06 | 2.649E-03 | FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 8.761E-06 | 2.847E-03 | FABP3, LMNA, PPARD, PPARG, PTGS2, TERT, TLR2 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.236E-05 | 3.686E-03 | PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.304E-05 | 3.838E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 1.699E-05 | 4.742E-03 | FABP3, PPARA, PPARG, TLR2 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 1.852E-05 | 4.802E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 1.852E-05 | 4.802E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.852E-05 | 4.802E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 1.852E-05 | 4.802E-03 | FABP3, PPARG |
| BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 2.232E-05 | 5.719E-03 | PPARA, PPARG, PTGS1, PTGS2 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.627E-05 | 6.501E-03 | FFAR1, FFAR4, HPGD, NR1I2, PPARA, PPARD, PPARG, TLR2, TSHR |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.952E-05 | 7.218E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0045600; positive regulation of fat cell differentiation | 4.000E-05 | 9.266E-03 | PPARD, PPARG, PTGS2 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 4.192E-05 | 9.596E-03 | NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 4.231E-05 | 9.596E-03 | ALDH1A1, ALOX15, HPGD, PPARD, PPARG, PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0047484; regulation of response to osmotic stress | 4.436E-05 | 9.959E-03 | ABCB1, PTGS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 6.963E-13 | 4.178E-11 | FABP2, FABP3, FABP4, FABP5, PPARG, PPARA, PPARD |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 3.883E-07 | 1.165E-05 | FABP4, PTGS2, TSHR, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.189E-05 | 8.378E-04 | ALOX15, PTGS2, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.436E-04 | 3.654E-03 | ALOX15, PTGS2, PTGS1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 2.895E-03 | 3.474E-02 | PTGS2, TLR2 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 5.461E-03 | 5.461E-02 | FAAH, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 9.033E-03 | 7.742E-02 | PPARG, PTGS2, PPARD |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.997E-02 | 1.331E-01 | PPARA, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.653E-02 | 1.240E-01 | HPGD, PPARG |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.104E-01 | 1.673E-01 | TLR2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; FFAR1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
